{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "", "tokens": ["Conclusion"], "sentence": "Conclusion", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S2", "tokens": ["CD4", "+", "T", "cells", "from", "active", "RA", "patients", "are", "characterized", "by", "their", "resistance", "to", "IL-10", "inhibition", "of", "IFN-gamma", "production", ",", "due", "to", "constitutive", "STAT3", "phosphorylation", "and", "impaired", "IL-10", "-", "mediated", "STAT3", "activation", "."], "sentence": "CD4 + T cells from active RA patients are characterized by their resistance to IL-10 inhibition of IFN-gamma production , due to constitutive STAT3 phosphorylation and impaired IL-10 - mediated STAT3 activation .", "event_mentions": [], "entity_mentions": [{"id": "T1", "text": "CD4", "entity_type": "Protein", "start": 0, "end": 0}, {"id": "T2", "text": "IL-10", "entity_type": "Protein", "start": 14, "end": 14}, {"id": "T3", "text": "IFN-gamma", "entity_type": "Protein", "start": 17, "end": 17}, {"id": "T4", "text": "STAT3", "entity_type": "Protein", "start": 23, "end": 23}, {"id": "T5", "text": "IL-10", "entity_type": "Protein", "start": 27, "end": 27}, {"id": "T6", "text": "STAT3", "entity_type": "Protein", "start": 30, "end": 30}]}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S3", "tokens": ["The", "defective", "STAT3", "signaling", "is", "possibly", "associated", "with", "SOCS1", "predominance", "over", "SOCS3", "."], "sentence": "The defective STAT3 signaling is possibly associated with SOCS1 predominance over SOCS3 .", "event_mentions": [], "entity_mentions": [{"id": "T7", "text": "STAT3", "entity_type": "Protein", "start": 2, "end": 2}, {"id": "T8", "text": "SOCS1", "entity_type": "Protein", "start": 8, "end": 8}, {"id": "T9", "text": "SOCS3", "entity_type": "Protein", "start": 11, "end": 11}]}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S4", "tokens": ["These", "abnormalities", "in", "active", "RA", "are", "thought", "to", "be", "induced", "mainly", "after", "chronic", "exposure", "to", "high", "concentrations", "of", "IL-6", "."], "sentence": "These abnormalities in active RA are thought to be induced mainly after chronic exposure to high concentrations of IL-6 .", "event_mentions": [], "entity_mentions": [{"id": "T10", "text": "IL-6", "entity_type": "Protein", "start": 18, "end": 18}]}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S5", "tokens": ["The", "limited", "efficacy", "of", "IL-10", "treatment", "of", "RA", "patients", "[", "50", "]", "may", "be", "explained", "in", "part", "by", "the", "unresponsiveness", "to", "IL-10", "of", "inflammatory", "cells", ",", "including", "T", "cells", "."], "sentence": "The limited efficacy of IL-10 treatment of RA patients [ 50 ] may be explained in part by the unresponsiveness to IL-10 of inflammatory cells , including T cells .", "event_mentions": [], "entity_mentions": [{"id": "T11", "text": "IL-10", "entity_type": "Protein", "start": 4, "end": 4}, {"id": "T12", "text": "IL-10", "entity_type": "Protein", "start": 21, "end": 21}]}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S6", "tokens": ["On", "the", "contrary", ",", "the", "therapeutic", "efficacy", "of", "anti", "-", "IL-6", "receptor", "antibody", "has", "been", "reported", "in", "RA", "patients", "[", "51", "]", ",", "and", "one", "of", "the", "effects", "of", "this", "therapy", "may", "be", "to", "normalize", "T", "cells", "through", "the", "inhibition", "of", "IL-6", "-", "dependent", "STAT3", "activation", "."], "sentence": "On the contrary , the therapeutic efficacy of anti - IL-6 receptor antibody has been reported in RA patients [ 51 ] , and one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6 - dependent STAT3 activation .", "event_mentions": [], "entity_mentions": [{"id": "T13", "text": "IL-6 receptor", "entity_type": "Protein", "start": 10, "end": 11}, {"id": "T14", "text": "IL-6", "entity_type": "Protein", "start": 41, "end": 41}, {"id": "T15", "text": "STAT3", "entity_type": "Protein", "start": 44, "end": 44}]}
{"doc_id": "PMC-1064873-15-Conclusion.txt", "sent_id": "S7", "tokens": ["More", "specific", "therapy", "targeting", "STAT3", "activation", "will", "be", "awaited", ";", "for", "example", ",", "the", "induction", "of", "the", "SOCS3", "gene", ",", "the", "efficacy", "of", "which", "has", "been", "demonstrated", "in", "animal", "models", "[", "37", "]", "."], "sentence": "More specific therapy targeting STAT3 activation will be awaited ; for example , the induction of the SOCS3 gene , the efficacy of which has been demonstrated in animal models [ 37 ] .", "event_mentions": [], "entity_mentions": [{"id": "T16", "text": "STAT3", "entity_type": "Protein", "start": 4, "end": 4}, {"id": "T17", "text": "SOCS3", "entity_type": "Protein", "start": 17, "end": 17}]}
